FDA Hematology approvals in 2018
FDA highlights approvals in 2018 at recent ASH meeting in San Diego. 2018 saw 32 FDA approvals in hematology including 12 NMEs & 5 biosimilars. 8 had pediatric indications. 6 were for 1st-line indications. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm #FDA #Approvals #hematology #oncology #2018
Can you guess who the top 10 cancer drug makers of 2024 will be...see FiercePharma special report.
Top 10 oncology companies by 2024 per FiercePharma
Value: Oncologists disagree on use of value to guide cancer treatments Author
A new study recently published in Value in Health by Risha Gidwani-Marszowski, DrPH, a health economist at the VA Palo Alto Health Care System and at Stanford. Click image to read full article Image by Nick Youngson "One of the most interesting things we found through this work is that the divergent views exist at a very basic level — the definition of value. For example, in defini
Top Selling Drugs of 2018? 5 of 10 predicted be Oncology Products
EvaluatePharma projects the best sellers of 2018. #2018 #drugs #pharmaceuticals #oncology
